PT1137436E - Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 - Google Patents

Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 Download PDF

Info

Publication number
PT1137436E
PT1137436E PT99965991T PT99965991T PT1137436E PT 1137436 E PT1137436 E PT 1137436E PT 99965991 T PT99965991 T PT 99965991T PT 99965991 T PT99965991 T PT 99965991T PT 1137436 E PT1137436 E PT 1137436E
Authority
PT
Portugal
Prior art keywords
ctla
self antigens
stimulation
blocking agents
against self
Prior art date
Application number
PT99965991T
Other languages
English (en)
Inventor
James Patrick Allison
Arthur A Hurwitz
Andrea Vanelsas
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of PT1137436E publication Critical patent/PT1137436E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT99965991T 1998-12-03 1999-12-03 Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4 PT1137436E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11076198P 1998-12-03 1998-12-03

Publications (1)

Publication Number Publication Date
PT1137436E true PT1137436E (pt) 2008-09-15

Family

ID=22334796

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99965991T PT1137436E (pt) 1998-12-03 1999-12-03 Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4

Country Status (11)

Country Link
EP (1) EP1137436B1 (pt)
JP (1) JP5341287B2 (pt)
AT (1) ATE397457T1 (pt)
AU (1) AU774962B2 (pt)
CA (1) CA2352783C (pt)
CY (1) CY1108318T1 (pt)
DE (1) DE69938871D1 (pt)
DK (1) DK1137436T3 (pt)
ES (1) ES2308857T3 (pt)
PT (1) PT1137436E (pt)
WO (1) WO2000032231A1 (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
ES2402546T3 (es) 2000-06-28 2013-05-06 Genetics Institute, Llc Moléculas PD-L2: nuevos ligandos de PD-1 y usos de lso mismos
PT2206517T (pt) 2002-07-03 2023-11-07 Tasuku Honjo Composições de imunopotenciação contendo anticorpos anti-pd-l1
CN1240436C (zh) * 2002-08-28 2006-02-08 上海益众生物技术有限公司 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用
JP2006522101A (ja) * 2003-03-12 2006-09-28 デューク・ユニバーシティー オリゴヌクレオチド類似体
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
KR101600225B1 (ko) 2005-06-08 2016-03-04 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
CA2630157C (en) 2005-12-07 2018-01-09 Medarex, Inc. Ctla-4 antibody dosage escalation regimens
CA2744449C (en) 2008-11-28 2019-01-29 Emory University Methods for the treatment of infections and tumors
CN102740887B (zh) 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US8435516B2 (en) 2009-10-12 2013-05-07 Pfizer Inc. Cancer treatment
DK2844282T3 (da) * 2012-05-04 2019-07-15 Pfizer Prostata-associerede antigener og vaccine-baserede immunterapiregimener
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EA201691073A1 (ru) 2013-12-05 2016-12-30 РФЕМБ ХОЛДИНГС, ЭлЭлСи Иммунотерапия рака с помощью радиочастотного электрического пробоя мембраны (rf-emb)
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
NZ734144A (en) 2014-12-31 2023-06-30 Checkmate Pharmaceuticals Inc Combination tumor immunotherapy
PT3273992T (pt) 2015-03-23 2020-08-21 Jounce Therapeutics Inc Anticorpos para icos
EP3303394B1 (en) 2015-05-29 2020-04-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CA3011460A1 (en) * 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
AU2017373944B2 (en) 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
CN110300599A (zh) 2016-12-07 2019-10-01 艾吉纳斯公司 抗体和其使用方法
JP2020509037A (ja) 2017-02-28 2020-03-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ワクチンに対する免疫応答を増強するための、ａｄｃｃが増強された抗ｃｔｌａ−４抗体の使用
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112105645A (zh) 2018-04-18 2020-12-18 Xencor股份有限公司 Il-15/il-15ra异二聚体fc融合蛋白及其用途
US20210236694A1 (en) * 2018-05-03 2021-08-05 The Johns Hopkins University Induction of anti-tumoral immune microenvironments
WO2020072821A2 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
CR20210239A (es) 2018-10-12 2021-12-15 Xencor Inc Proteínas de fusión de il-15/il-15ralfa-fc dirigidas a pd-1 y usos de las mismas en terapias combinadas
WO2021067863A2 (en) 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP7405361B2 (ja) 2019-10-21 2023-12-26 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
JP7498889B2 (ja) 2020-01-30 2024-06-13 東亞合成株式会社 Ｃｔｌａ４とｂ７タンパク質との結合を抑制するペプチドおよびその利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) * 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
CN1371416B (zh) * 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用

Also Published As

Publication number Publication date
ES2308857T3 (es) 2008-12-01
CA2352783C (en) 2012-04-10
JP5341287B2 (ja) 2013-11-13
WO2000032231A1 (en) 2000-06-08
ATE397457T1 (de) 2008-06-15
JP2002531416A (ja) 2002-09-24
EP1137436B1 (en) 2008-06-04
AU774962B2 (en) 2004-07-15
CA2352783A1 (en) 2000-06-08
AU2164900A (en) 2000-06-19
DK1137436T3 (da) 2008-10-13
EP1137436A1 (en) 2001-10-04
CY1108318T1 (el) 2014-02-12
DE69938871D1 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
PT1137436E (pt) Estimulação das células t contra auto-antigénios por meio de agentes bloqueadores de ctla-4
TW376320B (en) Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
CA2149329A1 (en) Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
ZA944347B (en) The use of cetrorelix and other nona- and decapeptides in the preparation of a medicament for combating aids and for growth stimulation
EP1025856A3 (en) Methods for modulating T Cell unresponsiveness
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1997002046A3 (de) Saccharid-konjugate
ATE420175T1 (de) C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
WO2002066044A3 (en) Method for dendritic cells based immunotherapy of tumors using combination therapy
FR2772622B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, defibrillateur et/ou cardioverteur, de type multisite configurable
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
AU8239298A (en) Nucleotide-comprising composition
DK0855916T3 (da) Farmaceutisk præparat indeholdende en Activin-stimulator
CA2194485A1 (en) Endothelial lining effects and treatment of vasospastic disorders
IL131478A0 (en) Methods for treatment of scar tissue
GB0102145D0 (en) Substances
GB2204497A (en) Electrode assembly for transdermal drug delivery
PL330535A1 (en) Novel systems for transcutaneous administration of trimegestone, method of preparing them for use and their application as therapeutic agents
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
FR2786699B1 (fr) Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles
MD1119G2 (ro) Metodă de tratament al afecţiunilor inflamatorii ale organelor genitale feminine
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten